home / stock / olma / olma news

OLMA News and Press, Olema Pharmaceuticals Inc. From 10/12/23

Stock Information
Company Name: Olema Pharmaceuticals Inc.
Stock Symbol: OLMA
Market: NASDAQ
Website: olema.com
Menu
OLMA OLMA Quote OLMA Short OLMA News OLMA Articles OLMA Message Board
Get OLMA Alerts

News, Short Squeeze, Breakout and More Instantly...
OLMA - Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity

SAN FRANCISCO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ( “Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women...
OLMA - Olema Oncology Announces Expansion of Collaboration Agreement with Novartis

Amended clinical collaboration and supply agreement increases the palazestrant/ribociclib combination Phase 1/2 clinical study size to approximately 60 patients Expanded study supports the potential late-stage development of palazestrant in first-line advanced or metastatic breast cance...

OLMA - Olema Pharmaceuticals director discloses sale of 25,000 shares

2023-10-04 10:52:02 ET More on Olema Pharmaceuticals Olema: Two-Pronged Approach To Treat Breast Cancer Patients Olema: Contrarian Small Cap Oncology Biotech (Reiterating Buy) Olema Pharmaceuticals up 6% on $180M financing Seeking Alpha’s Quant Rating ...

OLMA - Olema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

SAN FRANCISCO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ( “Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women&#x...
OLMA - Olema: Two-Pronged Approach To Treat Breast Cancer Patients

2023-09-18 15:20:36 ET Summary Initiation of the pivotal OPERA-01 study, using palazestrant for the treatment of 2nd-line/3rd-line HR+/HER2- metastatic breast cancer patients, expected in Q4 of 2023. Monotherapy results from the phase 2 study, using palazestrant for the treatment ...

OLMA - Olema Pharmaceuticals gains after 10% owner BVF PARTNERS L P/IL buys more shares

2023-09-15 12:34:36 ET Olema Pharmaceuticals ( NASDAQ: OLMA ) gains 10% after the company disclosed that 10% owner BVF PARTNERS L P/IL bought 1.5M common shares at $9.84 for total transaction value of $14.81M. Over the past 3 months, there has been 5 insider trades, with ...

OLMA - Olema Oncology to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s...
OLMA - CGC, VNDA and TSE among mid-day movers

2023-09-05 13:07:33 ET Gainers: Helius Medical Technologies ( HSDT ) +a55% . Novo Integrated Sciences ( NVOS ) +38% . Shengfeng Development Limited ( SFWL ) +29% . Cibus ( CBUS ) +28% . Cellectar Biosciences ( CLRB ) +28% . C...

OLMA - Olema Pharmaceuticals up 6% on $180M private placement

2023-09-05 08:07:41 ET More on Olema Pharmaceuticals Seeking Alpha’s Quant Rating on Olema Pharmaceuticals Financial information for Olema Pharmaceuticals Olema: Contrarian Small Cap Oncology Biotech (Reiterating Buy) Olema, Arvinas spike after analyst...

OLMA - Olema Oncology Announces Combined Financing for Up to $180 Million

$130 million equity private placement led by Paradigm BioCapital with participation by Lightspeed Venture Partners, Deep Track Capital, BVF Partners L.P., Cormorant Asset Management, Vivo Capital, Logos Capital, and Woodline Partners LP Senior secured credit facility for up to $50 milli...
Previous 10 Next 10